COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company has submitted a preliminary Request For Designation (RFD) to the FDA for its first wound care product. The RFD submission is part of a process with the FDA for determining which agency component will have primary jurisdiction for a drug, device or biological product.
